secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0000929638-23-003464
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene appoints Lota Zoth to Board as Audit Committee Chair
-----------------------------------------------------------

- Lota S. Zoth, CPA, appointed as Class I Director, effective Dec 18, 2023.
- Zoth will serve as Audit Committee Chair; Board expanded from four to five members.
- She brings 20+ years of financial and audit experience, including CFO at MedImmune.
- Currently serves on boards of Lumos Pharma, Inovio Pharmaceuticals, and 89 Bio.
- Standard independent director compensation plan applies; no related-party transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000092963823003464/0000929638-23-003464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000092963823003464/a8k.htm
  HTML page:      https://secwatch.observer/filing/0000929638-23-003464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer